Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body's innate immunity many of w... Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body's innate immunity many of which the company has outlicensed to partners to commercialize. Helix BioMedix, Inc., is committed to building long term shareholder value through development of novel drugs for rare dermatological conditions with unmet needs and strategic management of our diverse peptide library. 더 보기
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2012. Third Quarter 2012...
Helix BioMedix, Inc. (OTCQB: HXBM) (the “Company”), a developer of bioactive peptides, today announced that it has filed a Schedule 13E-3 and related preliminary proxy statement...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012. Second Quarter 2012...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the first quarter ended March 31, 2012. First Quarter 2012...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the year ended December 31, 2011. 2011 Financial and Business...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that it has been granted four new U.S. and foreign patents, further strengthening the...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s third quarter ended September 30, 2011. Third...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s second quarter ended June 30, 2011. Second...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that three new anti-blemish products developed by the company have been launched by sk:n –...
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s first quarter ended March 31, 2011. First Quarter...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | CS |
12 | -6 | -33.3333333333 | 18 | 18 | 12 | 183 | 15.45454545 | CS |
26 | -11.5 | -48.9361702128 | 23.5 | 23.5 | 12 | 153 | 17.51383178 | CS |
52 | -11.27 | -48.4314568113 | 23.27 | 23.5 | 12 | 133 | 19.40121859 | CS |
156 | -9.99999999998E-5 | -0.000833326388945 | 12.0001 | 26 | 12 | 199 | 20.6102671 | CS |
260 | -29.2 | -70.8737864078 | 41.2 | 41.2 | 12 | 222 | 24.00222176 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관